<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27203739</article-id><article-id pub-id-type="pmc">5130041</article-id><article-id pub-id-type="publisher-id">9442</article-id><article-id pub-id-type="doi">10.18632/oncotarget.9442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Paper</subject></subj-group></article-categories><title-group><article-title>Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Bao-tian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zhu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Pei-xian</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Jia-yang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chuang-zhen</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China</aff><aff id="A2"><sup>2</sup> Department of Nosocomial Infection Management, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Chuang-zhen Chen, <email>stccz@139.com</email></corresp><corresp id="cor2">Jia-yang Lu, <email>tianjia2025@163.com</email></corresp></author-notes><pub-date pub-type="collection"><day>28</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>5</month><year>2016</year></pub-date><volume>7</volume><issue>26</issue><fpage>40746</fpage><lpage>40755</lpage><history><date date-type="received"><day>11</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Huang et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>This study aims to compare the radiobiological response of two stereotactic body radiotherapy (SBRT) schedules for patients with stage I peripheral non-small cell lung cancer (NSCLC) using radiobiological modeling methods. Volumetric modulated arc therapy (VMAT)-based SBRT plans were designed using two dose schedules of 1 &#x000d7; 34 Gy (34 Gy in 1 fraction) and 4 &#x000d7; 12 Gy (48 Gy in 4 fractions) for 19 patients diagnosed with primary stage I NSCLC. Dose to the gross target volume (GTV), planning target volume (PTV), lung and chest wall (CW) were converted to biologically equivalent dose in 2 Gy fraction (EQD<sub>2</sub>) for comparison. Five different radiobiological models were employed to predict the tumor control probability (TCP) value. Three additional models were utilized to estimate the normal tissue complication probability (NTCP) value for the lung and the modified equivalent uniform dose (mEUD) value to the CW. Our result indicates that the 1 &#x000d7; 34 Gy dose schedule provided a higher EQD<sub>2</sub> dose to the tumor, lung and CW. Radiobiological modeling revealed that the TCP value for the tumor, NTCP value for the lung and mEUD value for the CW were 7.4% (in absolute value), 7.2% (in absolute value) and 71.8% (in relative value) higher on average, respectively, using the 1 &#x000d7; 34 Gy dose schedule.</p></abstract><kwd-group><kwd>radiobiological modeling</kwd><kwd>dose schedule</kwd><kwd>stereotactic body radiotherapy</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Stereotactic body radiation therapy (SBRT) is an effective and well-tolerated noninvasive treatment for patients with medically inoperable non-small cell lung cancer (NSCLC) [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. Results from recent investigations demonstrate that SBRT treatment for early stage lung cancer can achieve outcomes comparable with surgical resection [<xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref>].</p><p>Although SBRT treatment for NSCLC has offered encouraging outcomes, investigations into the benefits of single and multiple dose schedules remain ongoing [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>]. To date, there are no clinical results comparing the outcomes between single and multiple fraction schedules; thus, the problem requires further investigation.</p><p>Radiobiological modeling is a method used to simulate the treatment outcome of the tumor and normal tissues using mathematical calculations with parameters generated from fitting the clinical trials. This method has the advantage of linking the dosimetric variation with radiobiological responses and was recently used to predict the feasibility of dose escalation for esophageal cancer and primary prostate cancer [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>].</p><p>Therefore, the study mainly aims to compare the dose response between single and multiple fraction SBRT dose schedules in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP) using the method of radiobiological modeling. Given that a dose of 34 Gy in a single fraction [<xref rid="R11" ref-type="bibr">11</xref>] and 48 Gy in four fractions [<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref>] stand as the maximal and the most widely used dose schedules, respectively, it is important to demonstrate their feasibility, safety, and efficacy. Thus, these two fractionation schemes are worthy of comparison in this study.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Patient characteristics</title><p>The patients' characteristics are listed in Table <xref ref-type="table" rid="T1">1</xref>. In total, 14 of the patients suffered from T1 lesions and 5 of them suffered from T2 lesions. The median volume of gross target volume (GTV) and planning target volume (PTV) were 8.8 &#x000b1;10.4 and 36.9 &#x000b1;24.9 cm<sup>3</sup>, respectively.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of 19 patients with NSCLC undergoing SBRT</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Patient</th><th align="center" valign="middle" rowspan="1" colspan="1">Gender</th><th align="center" valign="middle" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" rowspan="1" colspan="1">Stage<xref rid="tfn_001" ref-type="table-fn">*</xref></th><th align="center" valign="middle" rowspan="1" colspan="1">GTV (cm<sup>3</sup>)</th><th align="center" valign="middle" rowspan="1" colspan="1">PTV (cm<sup>3</sup>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">8.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">9.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">20.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">16.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">23.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">27.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">32.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">23.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">39.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">31.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9</td><td align="center" valign="middle" rowspan="1" colspan="1">28.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">63.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">10.3</td><td align="center" valign="middle" rowspan="1" colspan="1">39.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6</td><td align="center" valign="middle" rowspan="1" colspan="1">40.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">21.0</td><td align="center" valign="middle" rowspan="1" colspan="1">71.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">77</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">26.7</td><td align="center" valign="middle" rowspan="1" colspan="1">95.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">41.6</td><td align="center" valign="middle" rowspan="1" colspan="1">87.9</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: GTV = gross target volume; PTV = planning target volume;</p><p>M = Male; F = Female;</p><fn id="tfn_001"><label>*</label><p><italic>Note:</italic>According to American Joint Committee on Cancer (AJCC), 7th edition.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2_2"><title>Dose comparison between the 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedule</title><p>Dose to the GTV, PTV-GTV (PTV minus GTV), lung and chest wall (CW) between the two dose schedules after conversion to biologically equivalent dose in 2 Gy fractions (EQD<sub>2</sub>) were listed in Table <xref ref-type="table" rid="T2">2</xref>. All the dose comparisons were statistically significant with <italic>p</italic>-values &#x0003c; 0.05. Specifically, the 1 &#x000d7; 34 Gy schedule provided up to 47.1% and 44.1% higher dose on average for the GTV and PTV-GTV, respectively. Moreover, the 1 &#x000d7; 34 Gy schedule also added 3.1&#x02013;7.9% more dose on average to V<sub>10</sub>&#x02013;V<sub>60</sub> of the CW. However, the dose delivered to the lung was much smaller, with V<sub>5</sub>&#x02013;V<sub>70</sub> increasing by 1.0&#x02013;2.2%. The cumulative dose volume histogram (cDVH) of the GTV, PTV-GTV, lung and CW after EQD<sub>2</sub> dose conversion is presented in Figure <xref ref-type="fig" rid="F1">1</xref>. Dose distributions from the transversal, coronal and sagittal views are presented in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>EQD<sub>2</sub> dose comparison between 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedules</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Structures</th><th align="center" valign="middle" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" rowspan="1" colspan="1">1 &#x000d7; 34 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1">4 &#x000d7; 12 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">GTV</td><td align="center" valign="middle" rowspan="1" colspan="1">D<sub>mean</sub> (Gy)</td><td align="center" valign="middle" rowspan="1" colspan="1">167.6 &#x000b1; 6.0</td><td align="center" valign="middle" rowspan="1" colspan="1">113.9 &#x000b1; 3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PTV-GTV</td><td align="center" valign="middle" rowspan="1" colspan="1">D<sub>mean</sub> (Gy)</td><td align="center" valign="middle" rowspan="1" colspan="1">140.9 &#x000b1; 2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">97.8 &#x000b1; 1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="9" colspan="1">Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>5</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.9 &#x000b1; 5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">12.9 &#x000b1; 4.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>10</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.9 &#x000b1; 4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4 &#x000b1; 4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>20</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4 &#x000b1; 4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">7.2 &#x000b1; 3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>30</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7 &#x000b1; 3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5 &#x000b1; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>40</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.4 &#x000b1; 3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4 &#x000b1; 2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>50</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.6 &#x000b1; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6 &#x000b1; 1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>60</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9 &#x000b1; 2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>70</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4 &#x000b1; 2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D<sub>mean</sub> (Gy)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 &#x000b1; 7.3</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0 &#x000b1; 3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="7" colspan="1">CW</td><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>10</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">39.2 &#x000b1; 12.1</td><td align="center" valign="middle" rowspan="1" colspan="1">34.7 &#x000b1; 12.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>20</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">25.6 &#x000b1; 11.1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.7 &#x000b1; 8.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>30</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.5 &#x000b1; 8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 &#x000b1; 5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>40</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.7 &#x000b1; 5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.6 &#x000b1; 3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>50</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.1 &#x000b1; 4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 &#x000b1; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>60</sub> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0 &#x000b1; 3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D<sub>mean</sub> (Gy)</td><td align="center" valign="middle" rowspan="1" colspan="1">24.8 &#x000b1; 10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3 &#x000b1; 5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: GTV = gross target volume; PTV = planning target volume; PTV-GTV = PTV minus GTV. CW = chest wall; D<sub>mean</sub> = mean dose; V<sub>x</sub> was the volume of the organ receiving a dose of x Gy or more.</p></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>DVH of the GTV, PTV-GTV, lung and CW after EQD<sub>2</sub> conversion</title><p>(<bold>A</bold>) DVH of the GTV, (<bold>B</bold>) DVH of the PTV-GTV, (<bold>C</bold>) DVH of the lung, and (<bold>D</bold>) DVH of the CW. GTV = gross target volume; PTV = planning target volume; PTV-GTV = PTV minus GTV; CW = chest wall; EQD<sub>2</sub> = biologically equivalent dose in 2 Gy fractions.</p></caption><graphic xlink:href="oncotarget-07-40746-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Dose distribution from the transversal, coronal and sagittal views between the two dose schedules</title><p>The dose color wash slider was set at 15 Gy for the 1 &#x000d7; 34 Gy schedule and 23.59 Gy for the 4 &#x000d7; 12 Gy schedule (the same EQD<sub>2</sub> dose). (<bold>A</bold>) Dose distribution of the 1 &#x000d7; 34 Gy schedule. (<bold>B</bold>) Dose distribution of the 4 &#x000d7; 12 Gy schedule.</p></caption><graphic xlink:href="oncotarget-07-40746-g002"/></fig></sec><sec id="s2_3"><title>Dose response between the 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedule</title><p>By radiobiological modeling, we found that five TCP and two lung complication predicting models yielded similar results. Radiobiological modeling revealed that TCP value for the tumor and NTCP value for the lung were 7.4% and 7.2% higher (in absolute value), respectively, on average with the 1 &#x000d7; 34 Gy schedule compared with the 4 &#x000d7; 12 Gy schedule. The modified equivalent uniform dose (mEUD) value to the CW was also increased by 71.8% in relative value. Detailed information of TCP prediction in the five models is presented in Table <xref ref-type="table" rid="T3">3</xref>. Data regarding the NTCP for the lung and mEUD value to the CW between the two dose schedules are provided in Table <xref ref-type="table" rid="T4">4</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>TCP value between 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedule in five models</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" rowspan="1" colspan="1">1 &#x000d7; 34 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1">4 &#x000d7; 12 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mar (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">98.3 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">85.3 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fen (%)<xref rid="tfn_002" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">95.8 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">90.9 &#x000b1; 3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WN (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">94.3 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">85.5 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EUD (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">98.1 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">93.4 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nitin (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">98.1 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">92.6 &#x000b1; 2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">96.9 &#x000b1; 1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">89.5 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: Mar = Martel model; Fen = Fenwick model; WN = Webb-Nahum model; EUD = equivalent uniform dose model; Nitin = Nitin model.</p><fn id="tfn_002"><label>*</label><p><italic>Note:</italic> Indicates Fenwick model for TCP prediction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>NTCP value for the lung and mEUD value for the CW between 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedules</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" rowspan="1" colspan="1">1 &#x000d7; 34 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1">4 &#x000d7; 12 Gy</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" colspan="4" rowspan="1">Lung</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LKB (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6 &#x000b1; 10.2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.8 &#x000b1; 3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fen (%)<xref rid="tfn_003" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">11.6 &#x000b1; 8.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.6 &#x000b1; 9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4 &#x000b1; 2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">CW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mEUD (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">175.1 &#x000b1; 89.1</td><td align="center" valign="middle" rowspan="1" colspan="1">101.9 &#x000b1; 48.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: LKB = Lyman-Kutcher-Burman (LKB) model; Fen = Fenwick model; mEUD = modified equivalent uniform dose model; CW = chest wall.</p><fn id="tfn_003"><label>*</label><p><italic>Note:</italic> Indicates Fenwick model for NTCP estimation to the lung.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Our analysis of the dose response for stage I NSCLC using radiobiological modeling revealed that the TCP value for the tumor was 7.4% higher with the 1 &#x000d7; 34 Gy dose schedule. In addition, the NTCP value for the lung and mEUD value to the CW were increased by 7.2% in absolute value and 71.8% in relative value on average, respectively, compared with the 4 &#x000d7; 12 Gy schedule. To our knowledge, our study is the first to use different radiobiological models to predict TCP and NTCP data in single and multiple fraction dose schedules. We believe that our results can provide useful information for clinical SBRT treatment of lung lesion.</p><p>The incidence of radiation pneumonitis (RP) ranges from 10% to 20.3% [<xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>], and the median intervals to first graphical appearance were 4.2 and 2.5 months for grade 1 and grade 2&#x02013;3 RP, respectively [<xref rid="R18" ref-type="bibr">18</xref>]. Similarly, the incidence of CW toxicity ranged from 8.3% to 32.8% [<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref>] and frequently occurred greater than 6 months after the completion of therapy [<xref rid="R23" ref-type="bibr">23</xref>]. As the RP and CW pain are common radiotherapy-induced side effects for peripheral NSCLC patients undergoing SBRT, our study mainly focuses on predicting the complication probability of the lung and CW between the two dose schedules.</p><p>The 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy dose schedules have been widely used in SBRT treatment for lung cancer and many publications have reported their feasibility, safety and efficacy in clinical treatment. Hara et al reported that irradiation doses of &#x02265; 30 Gy resulted in 1-year local progression-free rates (LPFRs) of 93% in fifty tumors and Grade 3 respiratory symptoms were only noted in 1 patient [<xref rid="R11" ref-type="bibr">11</xref>]. Videtic et al observed 1-year local control of 86.2% and no grade 3 or higher toxicity with the 1 &#x000d7; 34 Gy schedule [<xref rid="R24" ref-type="bibr">24</xref>]. Nagata et al observed that 98% of 45 tumors were locally controlled during the follow-up period, and no pulmonary complications greater than Grade 3 were noted with the 4 &#x000d7;12 Gy scheme [<xref rid="R12" ref-type="bibr">12</xref>]. Kelley et al reported 81.8% local control at one year for the entire cohort and no grade 3 or greater toxicity adverse events were observed with the 4 &#x000d7; 12 Gy scheme for treatment of medically inoperable NSCLC patients [<xref rid="R13" ref-type="bibr">13</xref>]. The mentioned outcomes demonstrate comparable local control and incidences of adverse events between the two dose schedules. However, our finding that the TCP for the tumor and the risk of radiation-induced complication were higher with the 1 &#x000d7; 34 Gy schedule slightly differs from the results of these studies. Given that the study was comparing the TCP and NTCP using two schedules of prescription dose, it is not suitable to compare this study using radiobiological modeling with the clinical data of the previous study. How to better fit to clinical data with radiobiological models will be a subject of our future work.</p><p>The repopulation and reoxygenation in tumor cells are two problematic factors that should be taken into account during the radiobiological modeling of single and multiple fraction schedules. Single-fraction SBRT is a promising modality that has the potential to circumvent the problem of repopulation, which can occur during conventional, fractionated radiation therapy [<xref rid="R11" ref-type="bibr">11</xref>]. The impact of tumor cell repopulation could be ignored when accelerated repopulation was observed in less than 21 days [<xref rid="R25" ref-type="bibr">25</xref>], as noted in lung SBRT treatment. Regarding tumor reoxygenation, multiple fraction schedules are more beneficial for hypoxic tumors, as noted in lung tumors. However, the impact of inter-fraction fast reoxygenation of the hypoxic cells remains unclear, particularly in small fraction SBRT treatment. The recent investigation demonstrated a reduction in D<sub>50</sub> from 53.3 Gy for 2 fractions to 52.7 Gy for 5 fractions for hypofractionated treatments employing large doses per fraction due to a synergistic effect between intra-fraction repair and inter-fraction fast reoxygenation of the hypoxic cells [<xref rid="R26" ref-type="bibr">26</xref>]. The results indicated a slight impact of tumor cells' reoxygenation in less than 5 fractions of treatment. In summary, we believe the impact of repopulation and reoxygenation of the tumor cells on radiobiological modeling is negligible because our study only includes 1 and 4 fraction dose schedules.</p><p>The EQD<sub>2</sub> conversion in the present study was performed using the linear-quadratic (LQ) model that is derived from biological considerations of how cells could be killed by ionizing radiation [<xref rid="R27" ref-type="bibr">27</xref>]. The suitability of the LQ model for high doses has been intensely debated in recent years. Recently, increasing clinical evidence has confirmed the accuracy of LQ-based tumor control and normal tissue predicting models. Guckenberger et al suggested that the traditional LQ formalism is accurately modeled for stage I NSCLC patients undergoing fractionated SBRT based on 395 patients from 13 German and Austrian centers [<xref rid="R28" ref-type="bibr">28</xref>]. Shuryak et al also found that LQ-based TCP models can provide significantly better fits to single-fraction local control data for SBRT treatment of NSCLC compared with other models requiring extra terms at high doses [<xref rid="R29" ref-type="bibr">29</xref>]. Borst et al demonstrated that the LQ model was valid for estimating the toxicity probabilities of RP [<xref rid="R30" ref-type="bibr">30</xref>]. According to two clinical studies, we believe that the dose conversion in our study utilizing the LQ model is reliable.</p><p>The results of our analysis are dependent on the choice of radiobiological models and parameters used. Therefore, we used a series of models from the literature to confirm our result. Five TCP predicting models were used in the present study and the radiobiological parameters of four models were derived from clinical data. Particularly, the Nitin model was generated by retrospectively analyzing 504 NSCLC tumors treated with a variety of SBRT schedules [<xref rid="R31" ref-type="bibr">31</xref>]. Interestingly, different radiobiological models predicted similar trends, irrespective of the TCP or NTCP prediction, suggesting their feasibility in predicting the radiobiological response.</p><p>Although our study has predicted the dose response of 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy schedules, our study has some limitations. (1) Our analysis is mainly based on radiobiological modeling and the results should be confirmed in large prospective, randomized, controlled clinical trials. (2) We ignored the radiation-induced rib fracture in lung SBRT. Although several studies reported that the tumor-chest wall distance is a risk factor for rib fracture [<xref rid="R32" ref-type="bibr">32</xref>], no radiobiological model has been proposed to predict the incidence of this condition; thus, we could not easily evaluate rib fracture during the modeling.</p><p>In conclusion, radiobiological modeling analysis demonstrates that the 1 &#x000d7; 34 Gy dose schedule achieves 7.4% higher TCP prediction but also increases radiation-induced lung and CW complication probabilities by 7.2% (absolute value) and 71.8% (relative value), respectively, compared with the 4 &#x000d7; 12 schedule.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Ethics statement</title><p>The protocol was approved by the Ethics Committee of Cancer Hospital of Shantou University Medical College. Given that this is not a treatment-based study, our institutional review board waived the need for written informed consent from the participants. However, patient information was anonymous to protect their confidentiality.</p></sec><sec id="s4_2"><title>Patients selection</title><p>Nineteen patients previously diagnosed with peripheral stage I primary NSCLC and treated with radiotherapy were used in this study. A peripheral lesion was defined as the tumor &#x0003e; 2 cm in all directions around the proximal bronchial tree according to the definition in Radiation Therapy Oncology Group (RTOG) 0915 report [<xref rid="R33" ref-type="bibr">33</xref>]. Meanwhile, the tumor must be beyond 1 cm of major vessels, esophagus, heart, trachea, pericardium, brachial plexus and vertebral bodies. Inclusion criteria in the study included (1) histological confirmation of NSCLC prior to treatment, (2) stage T1N0M0 or T2N0M0 (maximal diameter &#x02264; 5 cm in any direction), (3) age &#x0003e; 18 years old.</p></sec><sec id="s4_3"><title>Computed tomography (CT) scanning</title><p>The patients were simulated on a supine position with a vacuum bag (Medtec Medical, Inc. Buffalo Grove, IL) or a thermoplastic mask (Guangzhou Klarity Medical &#x00026; Equipment Co., Ltd, Guangzhou, China) restricting system. All of the patients underwent respiratory-correlated four dimensional computed tomography (4DCT) scans using Brilliance CT with Big Bore (Cleveland, OH, USA). CT images were obtained at a 3-mm slice thickness during scanning. CT images were then transferred to an Eclipse treatment planning system (Version 10.0, Varian Medical System, Inc., Palo Alto, CA) for target delineation, organs at risk (OARs) contouring and treatment planning.</p></sec><sec id="s4_4"><title>Delineation of target volume and OARs</title><p>For target contouring, the internal target volume (ITV) was defined as the integration of the GTV on 10 phases of the 4DCT in the pulmonary windows. To account for set-up uncertainties and mechanical tolerance, a PTV was created by adding a uniform 5-mm margin expansion to the ITV. As to normal tissue contouring, the entire lung was limited to the air-inflated lung parenchyma, and the GTV and trachea/ipsilateral bronchus were excluded according to the RTOG 0915 report [<xref rid="R33" ref-type="bibr">33</xref>]. The CW was segmented from the corrected lung edges with a 20-mm expansion in the lateral, anterior, and posterior directions, excluding the lung volume and the mediastinal soft tissue [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>]. If the 20-mm expansion extended outside the body, the contour extended only as far as the external patient surface [<xref rid="R35" ref-type="bibr">35</xref>]. To avoid cumbersome contouring of the entire CW, we defined the CW within a 30-mm limit in the head-to-feet direction from the PTV [<xref rid="R34" ref-type="bibr">34</xref>].</p></sec><sec id="s4_5"><title>Treatment planning</title><p>Two dose schedules of 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy were prescribed. The treatment plans were designed using the Eclipse treatment planning system and conducted on the averaged 4DCT. Treatment plans were designed using the volumetric modulated arc therapy (VMAT) technique. All plans were designed on a TrueBeam Linac with a 6 MV flattening filter free (FFF) photon beam (maximum dose rate of 1400 MU/min). Plans were created using dual partial arcs to prevent irradiation from entering the contralateral lung. The collimator angles for all plans were set to 30&#x000b0; and 330&#x000b0; to minimize the contribution of the tongue-and-groove effect to the dose. Optimization was performed using the progressive resolution optimizer (PRO_10028) algorithm implemented in Eclipse 10.0. Dose calculation was performed using the anisotropic analytical algorithm (AAA_10028) with a grid resolution of 1 mm, considering the heterogeneity correction. The dose was normalized to 95% of the PTV receiving the prescribed dose. Prescription constraints, intermediate dose spillage and critical organ dose-volume limits in the two dose schedules were based on the criterion of the RTOG 0915 protocol [<xref rid="R33" ref-type="bibr">33</xref>]. Because RTOG 0915 report demands rapid dose fall-off beyond the target, the dose to the GTV was always greater than 120% of the prescribed dose.</p></sec><sec id="s4_6"><title>Dosimetric evaluation of the two dose schedules</title><p>For clarification, all doses mentioned in the article were converted to the EQD<sub>2</sub> dose using the LQ model. The target was divided into two substructures of GTV and PTV-GTV for comparison. For GTV and PTV-GTV, the evaluating parameter was the mean dose. For the lung and CW, the analysis included the mean dose and a set of dose volume histogram (DVH)-based values. cDVH for the target and OARs were reconstructed from the individual DVH. These histograms were obtained by averaging the corresponding volumes for each dose bin of 0.05 Gy. Dose distributions from the transversal, coronal and sagittal views between the two dose schedules were acquired at 15 Gy and 23.59 Gy (with the same EQD<sub>2</sub> dose) for the 1 &#x000d7; 34 Gy and 4 &#x000d7; 12 Gy schedules, respectively.</p></sec><sec id="s4_7"><title>Radiobiological modeling</title><p>Both the TCP and NTCP were calculated using in-house developed programs using MATLAB 7.0 (MathWorks, USA). The TCP was calculated using five different radiobiological models, including the Martel model [<xref rid="R36" ref-type="bibr">36</xref>], Fenwick model [<xref rid="R37" ref-type="bibr">37</xref>], Webb-Nahum model [<xref rid="R38" ref-type="bibr">38</xref>], equivalent uniform dose (EUD) model [<xref rid="R39" ref-type="bibr">39</xref>] and Nitin model [<xref rid="R31" ref-type="bibr">31</xref>]. We utilized the EUD-based Lyman-Kutcher-Burman (LKB) model [<xref rid="R40" ref-type="bibr">40</xref>] and Fenwick model [<xref rid="R37" ref-type="bibr">37</xref>] to estimate the NTCP for the lung. Radiation-induced CW toxicities were predicted for the 100-cc highest dose region using the mEUD model with moderate weighting [<xref rid="R20" ref-type="bibr">20</xref>]. A flow chart of the radiobiological modeling is presented in Figure <xref ref-type="fig" rid="F3">3</xref>. A detailed modeling procedure is described as follows: (1) cDVH statistics of GTV, lung and CW were imported into MATLAB software at a resolution of 0.05 Gy. (2) Then, the cDVH statistics were converted to the differential dose volume histogram (dDVH) according to the method of Hiram [<xref rid="R39" ref-type="bibr">39</xref>]. (3) To reduce the effects of heterogeneity in the two dose schedules, the program converted the dose in each volume element to an EQD<sub>2</sub> dose using the formula reported by other publications [<xref rid="R41" ref-type="bibr">41</xref>, <xref rid="R42" ref-type="bibr">42</xref>]. (4) Finally, the main program of different calculation models and the TCP and NTCP values were automatically calculated. An &#x003b1;/&#x003b2; value of 10 Gy was assigned for the tumor during the EQD<sub>2</sub> conversion [<xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R44" ref-type="bibr">44</xref>]. &#x003b1;/&#x003b2; values of 1.3 Gy and 3 Gy were assigned to estimate the NTCP for the lung and the mEUD value to the CW, respectively [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R45" ref-type="bibr">45</xref>]. Radiobiological parameters in the Martel, Fenwick, Nitin and mEUD models were obtained from the original work. Particularly, &#x003b1;<sub>m</sub> and &#x003c3;<sub>a</sub> values in the Webb-Nahum model were 0.30 and 0.1, respectively, by averaging 10 different histological sub-types of human lung cancer cell lines from Carmichael's report [<xref rid="R46" ref-type="bibr">46</xref>]. Cell density, &#x003c1; was equal to 10<sup>8</sup> according to Lindblom's work [<xref rid="R47" ref-type="bibr">47</xref>]. TCD<sub>50</sub> and &#x003b3;<sub>50</sub> parameters in the EUD model were obtained from Okunieff's work [<xref rid="R48" ref-type="bibr">48</xref>], and &#x003b1; was 0.30 according to Carmichael's report [<xref rid="R46" ref-type="bibr">46</xref>]. TD<sub>50</sub>, n and m in the LKB model were obtained from Seppenwoolde's result [<xref rid="R49" ref-type="bibr">49</xref>]. The larger the TCP, NTCP and mEUD values, the higher control rate for the tumor or higher incidence rate of complications in the lung and CW.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Flow chart of the radiobiological modeling</title><p>cDVH = cumulative dose volume histogram; dDVH = differential dose volume histogram; EQD<sub>2</sub> = biologically equivalent dose in 2 Gy fractions; TCP = tumor control probability; NTCP = normal tissue complication probability; Mar = Martel model; Fen = Fenwick model; WN = Webb-Nahum model; EUD = equivalent uniform dose model; Nitin = Nitin model; LKB = Lyman-Kutcher-Burman (LKB) model; mEUD = modified equivalent uniform dose model; CW = chest wall.</p></caption><graphic xlink:href="oncotarget-07-40746-g003"/></fig></sec><sec id="s4_8"><title>Statistical analysis</title><p>Median values and standard deviation are reported in the study. The Statistical Package for Social Sciences (SPSS, version 19.0, Chicago, IL) was used for statistical analysis. Comparison of the DVH-based parameters was performed using paired, two-tailed Student's <italic>t</italic>-test. A Wilcoxon matched-pair signed-rank test was alternatively used when the data did not follow a normal distribution. The results were considered statistically significant when <italic>p</italic>-values &#x0003c; 0.05.</p></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>No conflicts of interest from all participating authors.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>This work was sponsored by Medical Scientific Research Foundation of Guangdong Province (A2015534), Shantou Medical Science and Technology Planning Project [Grant No. (2015)123], Shantou University Medical College Clinical Research Enhancement Initiative (201424), Collaborative and Creative Center, Molecular Diagnosis and Personalized Medicine, Shantou University, Guangdong Province, China.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name></person-group><article-title>Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>66</volume><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">16765528</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Nyman</surname><given-names>J</given-names></name><name><surname>Hoyer</surname><given-names>M</given-names></name><name><surname>Wennberg</surname><given-names>B</given-names></name><name><surname>Gagliardi</surname><given-names>G</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Drugge</surname><given-names>N</given-names></name><name><surname>Ekberg</surname><given-names>L</given-names></name><name><surname>Friesland</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>KA</given-names></name><name><surname>Lund</surname><given-names>JA</given-names></name><name><surname>Morhed</surname><given-names>E</given-names></name><name><surname>Nilsson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3290</fpage><lpage>3296</lpage><pub-id pub-id-type="pmid">19414667</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmerman</surname><given-names>R</given-names></name><name><surname>Paulus</surname><given-names>R</given-names></name><name><surname>Galvin</surname><given-names>J</given-names></name><name><surname>Michalski</surname><given-names>J</given-names></name><name><surname>Straube</surname><given-names>W</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Fakiris</surname><given-names>A</given-names></name><name><surname>Bezjak</surname><given-names>A</given-names></name><name><surname>Videtic</surname><given-names>G</given-names></name><name><surname>Johnstone</surname><given-names>D</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Gore</surname><given-names>E</given-names></name><name><surname>Choy</surname><given-names>H</given-names></name></person-group><article-title>Stereotactic body radiation therapy for inoperable early stage lung cancer</article-title><source>JAMA</source><year>2010</year><volume>303</volume><fpage>1070</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">20233825</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solda</surname><given-names>F</given-names></name><name><surname>Lodge</surname><given-names>M</given-names></name><name><surname>Ashley</surname><given-names>S</given-names></name><name><surname>Whitington</surname><given-names>A</given-names></name><name><surname>Goldstraw</surname><given-names>P</given-names></name><name><surname>Brada</surname><given-names>M</given-names></name></person-group><article-title>Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort</article-title><source>Radiother Oncol</source><year>2013</year><volume>109</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24128806</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Schipper</surname><given-names>M</given-names></name><name><surname>Kidwell</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Lv</surname><given-names>F</given-names></name><name><surname>Orringer</surname><given-names>M</given-names></name><name><surname>Spring Kong</surname><given-names>FM</given-names></name></person-group><article-title>Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>90</volume><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">25052562</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Xuan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name></person-group><article-title>Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis</article-title><source>Radiother Oncol</source><year>2014</year><volume>112</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">25236716</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephans</surname><given-names>KL</given-names></name><name><surname>Djemil</surname><given-names>T</given-names></name><name><surname>Reddy</surname><given-names>CA</given-names></name><name><surname>Gajdos</surname><given-names>SM</given-names></name><name><surname>Kolar</surname><given-names>M</given-names></name><name><surname>Mason</surname><given-names>D</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>TW</given-names></name><name><surname>Mazzone</surname><given-names>P</given-names></name><name><surname>Machuzak</surname><given-names>M</given-names></name><name><surname>Mekhail</surname><given-names>T</given-names></name><name><surname>Videtic</surname><given-names>GM</given-names></name></person-group><article-title>A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience</article-title><source>J Thorac Oncol</source><year>2009</year><volume>4</volume><fpage>976</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">19633473</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Videtic</surname><given-names>GM</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Parker</surname><given-names>W</given-names></name><name><surname>Olivier</surname><given-names>KR</given-names></name><name><surname>Schild</surname><given-names>SE</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Urbanic</surname><given-names>JJ</given-names></name><name><surname>Choy</surname><given-names>H</given-names></name></person-group><article-title>A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>93</volume><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">26530743</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Partridge</surname><given-names>M</given-names></name><name><surname>Carrington</surname><given-names>R</given-names></name><name><surname>Hurt</surname><given-names>C</given-names></name><name><surname>Crosby</surname><given-names>T</given-names></name><name><surname>Hawkins</surname><given-names>MA</given-names></name></person-group><article-title>Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>90</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">25304796</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Hirata</surname><given-names>E</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Kwee</surname><given-names>SA</given-names></name></person-group><article-title>Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>91</volume><fpage>1017</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">25832692</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>R</given-names></name><name><surname>Itami</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Aruga</surname><given-names>T</given-names></name><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Sasano</surname><given-names>N</given-names></name><name><surname>Ohnishi</surname><given-names>K</given-names></name><name><surname>Kiyozuka</surname><given-names>M</given-names></name><name><surname>Fuse</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Naoi</surname><given-names>K</given-names></name><name><surname>Kohno</surname><given-names>Y</given-names></name></person-group><article-title>Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">16475150</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>Y</given-names></name><name><surname>Norihisa</surname><given-names>Y</given-names></name><name><surname>Mizowaki</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Mitsumori</surname><given-names>M</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Araki</surname><given-names>N</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Hiraoka</surname><given-names>M</given-names></name></person-group><article-title>Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><fpage>1427</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">16169670</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>KD</given-names></name><name><surname>Benninghoff</surname><given-names>DL</given-names></name><name><surname>Stein</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Byrnes</surname><given-names>RT</given-names></name><name><surname>Potters</surname><given-names>L</given-names></name><name><surname>Knisely</surname><given-names>JP</given-names></name><name><surname>Zinkin</surname><given-names>HD</given-names></name></person-group><article-title>Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy</article-title><source>Radiat Oncol</source><year>2015</year><volume>10</volume><fpage>120</fpage><pub-id pub-id-type="pmid">26018408</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibamoto</surname><given-names>Y</given-names></name><name><surname>Hashizume</surname><given-names>C</given-names></name><name><surname>Baba</surname><given-names>F</given-names></name><name><surname>Ayakawa</surname><given-names>S</given-names></name><name><surname>Miyakawa</surname><given-names>A</given-names></name><name><surname>Murai</surname><given-names>T</given-names></name><name><surname>Takaoka</surname><given-names>T</given-names></name><name><surname>Hattori</surname><given-names>Y</given-names></name><name><surname>Asai</surname><given-names>R</given-names></name></person-group><article-title>Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results</article-title><source>J Thorac Oncol</source><year>2015</year><volume>10</volume><fpage>960</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">26001145</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bongers</surname><given-names>EM</given-names></name><name><surname>Botticella</surname><given-names>A</given-names></name><name><surname>Palma</surname><given-names>DA</given-names></name><name><surname>Haasbeek</surname><given-names>CJ</given-names></name><name><surname>Warner</surname><given-names>A</given-names></name><name><surname>Verbakel</surname><given-names>WF</given-names></name><name><surname>Slotman</surname><given-names>B</given-names></name><name><surname>Ricardi</surname><given-names>U</given-names></name><name><surname>Senan</surname><given-names>S</given-names></name></person-group><article-title>Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs</article-title><source>Radiother Oncol</source><year>2013</year><volume>109</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">24183862</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Sarangkasiri</surname><given-names>S</given-names></name><name><surname>DeMarco</surname><given-names>M</given-names></name><name><surname>Turke</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>CW</given-names></name><name><surname>Dilling</surname><given-names>TJ</given-names></name></person-group><article-title>Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2013</year><volume>85</volume><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">22929858</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>Y</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Narabayashi</surname><given-names>M</given-names></name><name><surname>Sakanaka</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>N</given-names></name><name><surname>Miyagi</surname><given-names>K</given-names></name><name><surname>Norihisa</surname><given-names>Y</given-names></name><name><surname>Mizowaki</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Hiraoka</surname><given-names>M</given-names></name></person-group><article-title>Dose&#x02014;volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>83</volume><fpage>e545</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">22436782</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanemoto</surname><given-names>A</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Sugita</surname><given-names>T</given-names></name></person-group><article-title>Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer</article-title><source>Int J Clin Oncol</source><year>2015</year><volume>20</volume><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">25373854</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunlap</surname><given-names>NE</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Biedermann</surname><given-names>GB</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Benedict</surname><given-names>SH</given-names></name><name><surname>Sheng</surname><given-names>K</given-names></name><name><surname>Schefter</surname><given-names>TE</given-names></name><name><surname>Kavanagh</surname><given-names>BD</given-names></name><name><surname>Larner</surname><given-names>JM</given-names></name></person-group><article-title>Chest wall volume receiving &#x0003e; 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>76</volume><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">19427740</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woody</surname><given-names>NM</given-names></name><name><surname>Videtic</surname><given-names>GM</given-names></name><name><surname>Stephans</surname><given-names>KL</given-names></name><name><surname>Djemil</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name></person-group><article-title>Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>83</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">22197087</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephans</surname><given-names>KL</given-names></name><name><surname>Djemil</surname><given-names>T</given-names></name><name><surname>Tendulkar</surname><given-names>RD</given-names></name><name><surname>Robinson</surname><given-names>CG</given-names></name><name><surname>Reddy</surname><given-names>CA</given-names></name><name><surname>Videtic</surname><given-names>GM</given-names></name></person-group><article-title>Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT)</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>82</volume><fpage>974</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">21300453</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerwaard</surname><given-names>FJ</given-names></name><name><surname>Haasbeek</surname><given-names>CJ</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>Slotman</surname><given-names>BJ</given-names></name><name><surname>Senan</surname><given-names>S</given-names></name></person-group><article-title>Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>70</volume><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">18164849</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creach</surname><given-names>KM</given-names></name><name><surname>El Naqa</surname><given-names>I</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Olsen</surname><given-names>JR</given-names></name><name><surname>Parikh</surname><given-names>PJ</given-names></name><name><surname>Drzymala</surname><given-names>RE</given-names></name><name><surname>Bloch</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>CG</given-names></name></person-group><article-title>Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy</article-title><source>Radiother Oncol</source><year>2012</year><volume>104</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22385795</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Videtic</surname><given-names>GM</given-names></name><name><surname>Stephans</surname><given-names>KL</given-names></name><name><surname>Woody</surname><given-names>NM</given-names></name><name><surname>Reddy</surname><given-names>CA</given-names></name><name><surname>Zhuang</surname><given-names>T</given-names></name><name><surname>Magnelli</surname><given-names>A</given-names></name><name><surname>Djemil</surname><given-names>T</given-names></name></person-group><article-title>30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>90</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">25015198</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>JF</given-names></name><name><surname>Tome</surname><given-names>WA</given-names></name><name><surname>Fenwick</surname><given-names>JD</given-names></name><name><surname>Mehta</surname><given-names>MP</given-names></name></person-group><article-title>A challenge to traditional radiation oncology</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>60</volume><fpage>1241</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">15519797</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindblom</surname><given-names>E</given-names></name><name><surname>Dasu</surname><given-names>A</given-names></name><name><surname>Toma-Dasu</surname><given-names>I</given-names></name></person-group><article-title>Optimal fractionation in radiotherapy for non-small cell lung cancer - a modelling approach</article-title><source>Acta Oncol</source><year>2015</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Carlson</surname><given-names>DJ</given-names></name><name><surname>Brenner</surname><given-names>DJ</given-names></name></person-group><article-title>The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">24411596</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guckenberger</surname><given-names>M</given-names></name><name><surname>Klement</surname><given-names>RJ</given-names></name><name><surname>Allgauer</surname><given-names>M</given-names></name><name><surname>Appold</surname><given-names>S</given-names></name><name><surname>Dieckmann</surname><given-names>K</given-names></name><name><surname>Ernst</surname><given-names>I</given-names></name><name><surname>Ganswindt</surname><given-names>U</given-names></name><name><surname>Holy</surname><given-names>R</given-names></name><name><surname>Nestle</surname><given-names>U</given-names></name><name><surname>Nevinny-Stickel</surname><given-names>M</given-names></name><name><surname>Semrau</surname><given-names>S</given-names></name><name><surname>Sterzing</surname><given-names>F</given-names></name><name><surname>Wittig</surname><given-names>A</given-names></name><etal/></person-group><article-title>Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer</article-title><source>Radiother Oncol</source><year>2013</year><volume>109</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">24183066</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuryak</surname><given-names>I</given-names></name><name><surname>Carlson</surname><given-names>DJ</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Brenner</surname><given-names>DJ</given-names></name></person-group><article-title>High-dose and fractionation effects in stereotactic radiation therapy: Analysis of tumor control data from 2965 patients</article-title><source>Radiother Oncol</source><year>2015</year><volume>115</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">26058991</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borst</surname><given-names>GR</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><name><surname>Nijkamp</surname><given-names>J</given-names></name><name><surname>Hauptmann</surname><given-names>M</given-names></name><name><surname>Shirato</surname><given-names>H</given-names></name><name><surname>Bengua</surname><given-names>G</given-names></name><name><surname>Onimaru</surname><given-names>R</given-names></name><name><surname>de Josien Bois</surname><given-names>A</given-names></name><name><surname>Lebesque</surname><given-names>JV</given-names></name><name><surname>Sonke</surname><given-names>JJ</given-names></name></person-group><article-title>Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>77</volume><fpage>1596</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">20231066</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohri</surname><given-names>N</given-names></name><name><surname>Werner-Wasik</surname><given-names>M</given-names></name><name><surname>Grills</surname><given-names>IS</given-names></name><name><surname>Belderbos</surname><given-names>J</given-names></name><name><surname>Hope</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Kestin</surname><given-names>LL</given-names></name><name><surname>Guckenberger</surname><given-names>M</given-names></name><name><surname>Sonke</surname><given-names>JJ</given-names></name><name><surname>Bissonnette</surname><given-names>JP</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name></person-group><article-title>Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>84</volume><fpage>e379</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">22999272</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nambu</surname><given-names>A</given-names></name><name><surname>Onishi</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Tominaga</surname><given-names>L</given-names></name><name><surname>Kuriyama</surname><given-names>K</given-names></name><name><surname>Araya</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Maehata</surname><given-names>Y</given-names></name><name><surname>Komiyama</surname><given-names>T</given-names></name><name><surname>Marino</surname><given-names>K</given-names></name><name><surname>Koshiishi</surname><given-names>T</given-names></name><name><surname>Sawada</surname><given-names>E</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name></person-group><article-title>Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>68</fpage><pub-id pub-id-type="pmid">23391264</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Radiation Therapy Oncology Group</collab></person-group><article-title>A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer</article-title><year>2012</year><ext-link ext-link-type="uri" xlink:href="http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915">http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915</ext-link></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>FM</given-names></name><name><surname>Ritter</surname><given-names>T</given-names></name><name><surname>Quint</surname><given-names>DJ</given-names></name><name><surname>Senan</surname><given-names>S</given-names></name><name><surname>Gaspar</surname><given-names>LE</given-names></name><name><surname>Komaki</surname><given-names>RU</given-names></name><name><surname>Hurkmans</surname><given-names>CW</given-names></name><name><surname>Timmerman</surname><given-names>R</given-names></name><name><surname>Bezjak</surname><given-names>A</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Movsas</surname><given-names>B</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Okunieff</surname><given-names>P</given-names></name><etal/></person-group><article-title>Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><fpage>1442</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">20934273</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutter</surname><given-names>RW</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Abreu</surname><given-names>A</given-names></name><name><surname>Yorke</surname><given-names>E</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Rosenzweig</surname><given-names>KE</given-names></name></person-group><article-title>Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>82</volume><fpage>1783</fpage><lpage>1790</lpage><pub-id pub-id-type="pmid">21868173</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel</surname><given-names>MK</given-names></name><name><surname>Ten Haken</surname><given-names>RK</given-names></name><name><surname>Hazuka</surname><given-names>MB</given-names></name><name><surname>Kessler</surname><given-names>ML</given-names></name><name><surname>Strawderman</surname><given-names>M</given-names></name><name><surname>Turrisi</surname><given-names>AT</given-names></name><name><surname>Lawrence</surname><given-names>TS</given-names></name><name><surname>Fraass</surname><given-names>BA</given-names></name><name><surname>Lichter</surname><given-names>AS</given-names></name></person-group><article-title>Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients</article-title><source>Lung Cancer</source><year>1999</year><volume>24</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">10403692</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>JD</given-names></name><name><surname>Nahum</surname><given-names>AE</given-names></name><name><surname>Malik</surname><given-names>ZI</given-names></name><name><surname>Eswar</surname><given-names>CV</given-names></name><name><surname>Hatton</surname><given-names>MQ</given-names></name><name><surname>Laurence</surname><given-names>VM</given-names></name><name><surname>Lester</surname><given-names>JF</given-names></name><name><surname>Landau</surname><given-names>DB</given-names></name></person-group><article-title>Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2009</year><volume>21</volume><fpage>343</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">19231143</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>S</given-names></name><name><surname>Nahum</surname><given-names>AE</given-names></name></person-group><article-title>A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density</article-title><source>Phys Med Biol</source><year>1993</year><volume>38</volume><fpage>653</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">8346278</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname><given-names>HA</given-names></name><name><surname>Niemierko</surname><given-names>A</given-names></name></person-group><article-title>A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy</article-title><source>Phys Med</source><year>2007</year><volume>23</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">17825595</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luxton</surname><given-names>G</given-names></name><name><surname>Keall</surname><given-names>PJ</given-names></name><name><surname>King</surname><given-names>CR</given-names></name></person-group><article-title>A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)</article-title><source>Phys Med Biol</source><year>2008</year><volume>53</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18182685</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partridge</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>M</given-names></name><name><surname>Sardaro</surname><given-names>A</given-names></name><name><surname>Brada</surname><given-names>M</given-names></name></person-group><article-title>Dose escalation for non-small cell lung cancer: analysis and modelling of published literature</article-title><source>Radiother Oncol</source><year>2011</year><volume>99</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21458088</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Baardwijk</surname><given-names>A</given-names></name><name><surname>Tome</surname><given-names>WA</given-names></name><name><surname>van Elmpt</surname><given-names>W</given-names></name><name><surname>Bentzen</surname><given-names>SM</given-names></name><name><surname>Reymen</surname><given-names>B</given-names></name><name><surname>Wanders</surname><given-names>R</given-names></name><name><surname>Houben</surname><given-names>R</given-names></name><name><surname>Ollers</surname><given-names>M</given-names></name><name><surname>Lambin</surname><given-names>P</given-names></name><name><surname>De Ruysscher</surname><given-names>D</given-names></name></person-group><article-title>Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review</article-title><source>Radiother Oncol</source><year>2012</year><volume>105</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">23068707</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshy</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Sher</surname><given-names>DJ</given-names></name></person-group><article-title>Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>91</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">25636759</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Bassano</surname><given-names>DA</given-names></name><name><surname>Prasad</surname><given-names>SC</given-names></name><name><surname>Hahn</surname><given-names>SS</given-names></name><name><surname>Chung</surname><given-names>CT</given-names></name></person-group><article-title>The linear-quadratic model and fractionated stereotactic radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>57</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">14529790</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheenstra</surname><given-names>AE</given-names></name><name><surname>Rossi</surname><given-names>MM</given-names></name><name><surname>Belderbos</surname><given-names>JS</given-names></name><name><surname>Damen</surname><given-names>EM</given-names></name><name><surname>Lebesque</surname><given-names>JV</given-names></name><name><surname>Sonke</surname><given-names>JJ</given-names></name></person-group><article-title>Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">24331668</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Degraff</surname><given-names>WG</given-names></name><name><surname>Gamson</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>D</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Levitt</surname><given-names>ML</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Mitchell</surname><given-names>JB</given-names></name></person-group><article-title>Radiation sensitivity of human lung cancer cell lines</article-title><source>Eur J Cancer Clin Oncol</source><year>1989</year><volume>25</volume><fpage>527</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">2539297</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindblom</surname><given-names>E</given-names></name><name><surname>Antonovic</surname><given-names>L</given-names></name><name><surname>Dasu</surname><given-names>A</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Wersall</surname><given-names>P</given-names></name><name><surname>Toma-Dasu</surname><given-names>I</given-names></name></person-group><article-title>Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability</article-title><source>Radiat Oncol</source><year>2014</year><volume>9</volume><fpage>149</fpage><pub-id pub-id-type="pmid">24974778</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okunieff</surname><given-names>P</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><name><surname>Niemierko</surname><given-names>A</given-names></name><name><surname>Suit</surname><given-names>HD</given-names></name></person-group><article-title>Radiation dose-response of human tumors</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1995</year><volume>32</volume><fpage>1227</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">7607946</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppenwoolde</surname><given-names>Y</given-names></name><name><surname>Lebesque</surname><given-names>JV</given-names></name><name><surname>de Jaeger</surname><given-names>K</given-names></name><name><surname>Belderbos</surname><given-names>JS</given-names></name><name><surname>Boersma</surname><given-names>LJ</given-names></name><name><surname>Schilstra</surname><given-names>C</given-names></name><name><surname>Henning</surname><given-names>GT</given-names></name><name><surname>Hayman</surname><given-names>JA</given-names></name><name><surname>Martel</surname><given-names>MK</given-names></name><name><surname>Ten Haken</surname><given-names>RK</given-names></name></person-group><article-title>Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>55</volume><fpage>724</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">12573760</pub-id></element-citation></ref></ref-list></back></article>